Company Filing History:
Years Active: 2006-2009
Title: Innovations in Monoclonal Antibodies by Zhida Huang
Introduction
Zhida Huang is a prominent inventor based in Fremont, CA, known for his significant contributions to the field of monoclonal antibodies. With a total of two patents to his name, Huang has made remarkable advancements in the recognition of hormone receptors, which are crucial in cancer diagnostics and treatment.
Latest Patents
Huang's latest patents include a high affinity monoclonal antibody for recognizing the progesterone receptor (PR) and a similar antibody for the estrogen receptor (ER). The PR antibody, derived from lagomorphs, offers a notable advantage in immunohistochemistry by eliminating the need for target retrieval, which is a common requirement for existing PR antibodies. This innovation results in a very low background signal, enhancing the accuracy of assessments in human breast cancer. Comparative studies with clinical specimens have shown that Huang's PR antibody (clone SP2) outperforms the leading mouse monoclonal antibody (clone 1A6) currently available in the market. Similarly, his ER antibody (clone SP1) also demonstrates significant advantages, including the absence of target retrieval and low background, making it a valuable tool for evaluating ER status in breast cancer.
Career Highlights
Zhida Huang is associated with Spring Bioscience Corporation, where he continues to develop innovative solutions in the field of immunology. His work focuses on creating high affinity antibodies that can provide therapeutic benefits, particularly in the context of human breast cancer.
Collaborations
Huang collaborates with Haiying Xia, contributing to the advancement of antibody technologies and their applications in clinical settings.
Conclusion
Zhida Huang's innovative work in the development of monoclonal antibodies represents a significant leap forward in cancer diagnostics. His contributions are poised to enhance the accuracy and effectiveness of hormone receptor assessments in breast cancer, potentially leading to improved therapeutic outcomes.